- Aisel Health has recently obtained €1.7 million in pre-seed funding, with Caesar Ventures acting as the lead investor.
- The company, based in Copenhagen, is developing a clinical operating system for psychiatry that differs from standard AI scribe tools.
- The company intends to use the funds to enter the UK prior to its forthcoming seed round.
Although psychiatrists are able to produce session notes rapidly, it remains difficult to find information from previous sessions. Aisel Health plans to address this issue by improving information retrieval rather than merely speeding up the documentation process.
Caesar Ventures led the funding round, with additional support from Nordic Web Ventures, LifeX, Angel Invest, and the returning investors Rockstart and EIFO.
“Psychiatry doesn’t need more generic technology bolted onto an already overburdened workflow. It needs a product built around the realities of psychiatric care, where clinicians bring judgment, empathy and years of trained intuition, and the technology brings the speed, structure and ability to hold together every detail about every patient, in a way no human memory can,” said Augusta Klingsten Peytz, co-founder and chief executive of Aisel Health.
The market for mental health technology is projected to reach $10.08 billion by 2025 and will grow at a rate of 18.7% per year through 2035, driven by the adoption of AI and increasing demand for psychiatric care. However, patients still generally have to wait weeks or months for appointments in both the private and public sectors.
Tackling the challenge of information retrieval
The company, founded in 2024 by Klingsten Peytz and Christian Houen, chief product officer, converts interview recordings, documents, and patient accounts into structured insights that clinicians can access during consultations.
“We still have yet to overcome the human limitation of understanding everything that was ever written about every patient ever treated. That’s the problem we built Aisel to solve, “ Houen added.
London-based Limbic has raised around $14.7 million, with its Series A round being led by Khosla Ventures, while UK-based Thymia has raised $2.7 million for its gamified mental health assessments.
Likeminded, which is based in Berlin, has secured €1.5 million and specialises in corporate wellness rather than clinical documentation. JotPsych and Scribenote are more direct competitors; JotPsych raised $5 million for an AI behavioral health EHR, and Scribenote raised $8.2 million for scribe solutions in veterinary clinics. Both of them primarily focus on faster note-taking.
Aisel platform has been designed specifically with psychiatric workflows in mind, not by adapting general medicine or wellness applications. The company is currently collaborating with private clinics in Denmark, carrying out research partnerships with Region H and the University of Southern Denmark, and working with MedTech Growth at the Technical University of Denmark.
Who’s backing it, and what’s next
Carolin Gabor, the managing partner at Caesar Ventures and the 2025 KfW Capital Award winner for best female investor, is heading the round.
“Few problems in healthcare are as large or as overlooked as psychiatry’s, and few founders are as passionate about solving it as Augusta and Christian are,” she said.
Amol Sarva, managing partner at LifeX Ventures, added: “We look for European quality and diligence and American ambitions, and we’re thrilled to back Aisel as they prove both to change one of the biggest challenges of their generation.”
The team led by Aisel consists of both clinical and technical experts. The additional funding will be used to recruit more clinical and engineering personnel and will also support the company’s expansion into the UK, where it is already providing services to private psychiatry clients, prior to its intended seed round.
AI writers have addressed one issue in psychiatric care, but Aisel maintains that they have introduced a new one. If an operating system for psychiatry is to be successful, it should aim to reduce waiting lists rather than simply provide another platform for clinics to use.
